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The Testisin gene (PRSS21) encodes a glycosylphosphatidylinositol (GPI)-linked serine protease that exhibits testis tissue-specific
expression. Loss of Testisin has been implicated in testicular tumorigenesis, but its role in testis biology and tumorigenesis is not
known. Here we have investigated the role of CpG methylation in Testisin gene inactivation and tested the hypothesis that Testisin
may act as a tumour suppressor for testicular tumorigenesis. Using sequence analysis of bisulphite-treated genomic DNA, we find a
strong relationship between hypermethylation of a 385bp 50 CpG rich island of the Testisin gene, and silencing of the Testisin gene in
a range of human tumour cell lines and in 100% (eight/eight) of testicular germ cell tumours. We show that treatment of Testisin-
negative cell lines with demethylating agents and/or a histone deacetylase inhibitor results in reactivation of Testisin gene expression,
implicating hypermethylation in Testisin gene silencing. Stable expression of Testisin in the Testisin-negative Tera-2 testicular cancer
line suppressed tumorigenicity as revealed by inhibition of both anchorage-dependent cell growth and tumour formation in an SCID
mouse model of testicular tumorigenesis. Together, these data show that loss of Testisin is caused, at least in part, by DNA
hypermethylation and histone deacetylation, and suggest a tumour suppressor role for Testisin in testicular tumorigenesis.
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Testicular cancer is the most common malignancy affecting males
aged 14–40 (Liu et al, 2000; Jemal et al, 2002) with the incidence of
testicular germ cell tumours (TGCT) rising dramatically in recent
years (Zheng et al, 1996). If diagnosed early, testicular cancer has a
very high cure rate (Oliver, 1990, 2003). Nonetheless, there is a
significant minority of TGCT that are resistant or become
treatment resistant, suggesting that a better understanding of the
molecular biology of this cancer would be valuable with regard to
determinants of chemotherapeutic efficacy (Jones and Vasey,
2003).
TGCT commonly consist of two distinct histological subtypes,
seminomas and nonseminomatous TGCT, with the latter including
yolk sac, teratoma and mixed germ cell tumours. Somatic
mutations leading to TGCT include chromosome duplication, loss
of heterozygosity (LOH) and gene deletion (Sandberg et al, 1996;
Lutzker and Barnard, 1998; Looijenga and Oosterhuis, 1999;
Skotheim and Lothe, 2003). Epigenetic mechanisms are also
increasingly recognised as a major mechanism of gene inactivation
during TGCT progression. CG dinucleotide-rich regions, also
known as CpG islands, in or near the proximal promoter regions of
genes are targets for DNA methylation, leading to histone
deacetylation, chromatin condensation and effective transcrip-
tional silencing (Baylin et al, 1998; Herman, 1999). In normal cells,
CpG methylation is an important mechanism for regulating gene
expression, whereas in cancer cells, aberrant promoter methylation
or hypermethylation can lead to abnormal gene silencing,
including repression of tumour suppressor genes. An increasing
number of tumour suppressor genes have been recognised for
which epigenetic silencing is the predominant mechanism of gene
inactivation and for which somatic mutations are rare. While
several testicular tumour suppressor genes have now been
identified (Bartkova et al, 2000; Datta et al, 2001; Luo et al,
2001; Eyzaguirre and Gatalica, 2002; Honorio et al, 2003), only a
few, for example RASSF1A (Honorio et al, 2003), MGMT (Smith-
Sorensen et al, 2002), have been reported to be silenced in
testicular tumours through DNA hypermethylation.
Testisin was identified by virtue of its tissue-specific expression
in testis and its absence in TGCTs, suggesting that Testisin may
function as a tumour suppressor gene (Hooper et al, 1999).
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prone to mutations and deletions in multiple human cancers (Flint
et al, 1997). The Testisin gene encodes a member of the serine
protease family, a family of hydrolases that utilises the hydroxyl
group of a serine amino-acid residue to cleave a target peptide
bond (Rawlings and Barrett, 1994). Some members of this family
cleave a wide range of target sequences, whereas others are quite
narrow in their range of targets. Testisin belongs to a unique
subgroup of trypsin-like serine proteases, which includes prostasin
(Yu et al, 1994, 1995, 1996), murine and pancreasin (Bhagwandin
et al, 2003). These enzymes are synthesised with a distinct
carboxy-terminal peptide that is post-transcriptionally modified
with a glycosylphosphatidylinositol (GPI)-membrane anchor (Inoue
et al, 1998; Hooper et al, 1999; Honda et al, 2002; Netzel-Arnett
et al, 2003). Thus, these enzymes may be present in plasma
membranes or released from their anchor and secreted. The
physiological function of Testisin is still not clear. In the case of
prostasin, one role that has been identified is the regulation of
epithelial Naþ channel (ENaC) function that is critical for normal
salt and water balance (Vuagniaux et al, 2000; Tong et al, 2004).
The human Testisin gene (TEST1; PRSS21) is located within a
cluster of serine protease genes on chromosome 16p13.3 (Inoue
et al, 1999; Hooper et al, 2000) and consists of six exons ranging in
size from 27 to 354bp interspersed with five introns ranging in size
from 97 to 1985bp. Unusually for serine protease genes, the
human Testisin gene contains a 50 CpG island and a 50 CpG rich
region, which encompass the proximal promoter, transcription
and translation initiation sites, the 50 untranslated region and
coding/noncoding sequences spanning exons I–III (Hooper et al,
2000). The Testisin 50 proximal promoter lacks a TATA consensus
sequence, but contains a putative CCAAT box, three consensus-
binding sites for Sp1, two potential AP1 binding sites, one putative
NFkB binding site and several elements associated with testis-
specific expression (Hooper et al, 2000). Many of these sites
contain CpG dinucleotides located wholly within or bordering
their sequence that may be affected by CpG methylation. In
addition, the Testisin gene contains CpG dinucleotides located
downstream of the transcription initiation site that, when
methylated, may bind methyl-CpG binding proteins (MeCP), such
as MeCP2 and MeCP1, which could contribute to transcriptional
repression.
In the present study we have investigated the role of CpG
methylation in Testisin gene inactivation and examined possible
consequences for testicular tumorigenesis. Using the technique of
sequence analysis of sodium bisulphite-treated genomic DNA
(Clark et al, 1994), we find a strong correlation between
hypermethylation of the Testisin 50 region and loss of Testisin
mRNA expression both in human tumour cell lines and in primary
testicular tumour tissues. Additionally, inhibitors of gene methyla-
tion restore Testisin gene expression in Testisin-negative tumour
lines. Finally, ectopic expression of Testisin in Tera-2 testicular
tumour cells significantly suppressed tumorigenicity, providing
the first functional evidence for Testisin as a suppressor of
testicular tumour growth.
MATERIALS AND METHODS
Human tumour specimens and cell lines
Tissue from both normal and tumour-affected regions of
orchidectomised testes were collected at the time of surgery, snap
frozen in liquid nitrogen and stored at  801C for subsequent RNA
and genomic DNA isolation and analysis. Approval was obtained
from the relevant institutional ethics committees. The Tera-2
teratocarcinoma cell line (NTera-2 clone 13) (Fogh et al, 1977;
Thompson et al, 1984) and the embryonal carcinoma cell line GCT
27 C-4 were cultured in a mixture of MEM-alpha medium:HAMS
F12 (1:1) (Invitrogen Australia, Pty Ltd, Victoria, Australia)
supplemented with 10% foetal bovine serum (CSL, Parkville,
Australia), 50mgml
 1 penicillin, 50mgml
 1 streptomycin, 25mM
HEPES and 15mgml
 1 0.833% sodium hydroxide. The cervical
carcinoma cell lines HeLa S3 (ATCC No. CCL-2.2) and SiHa (ATCC
No. HTB-35) and the colon carcinoma cell line SW620 (ATCC No.
CCL-227) were cultured in RPMI 1640 (Invitrogen Australia, Pty
Ltd) supplemented with 10% foetal bovine serum, 50mgml
 1
penicillin and 50mgml
 1 streptomycin. All cell lines were cultured
in 5% CO2 and 95% humidified air atmosphere at 371C. Cell
viability was determined by Trypan blue dye exclusion and
mycoplasma-free status tested by Hoechst 33258 staining
(Chen, 1977).
RT–PCR and real-time PCR analyses
Total RNA was extracted using TRIZOL
s reagent (Invitrogen,
Victoria, Australia) as per the manufacturer’s instructions. The
RNA (2mg) was reverse transcribed using Superscriptt II reverse
transcriptase (Invitrogen Australia, Pty Ltd). PCR was performed
using 1–3ml of cDNA in a 25ml reaction containing 1ml (25ng) of
Testisin forward (50-CTGACTTCCATGCCATCCTT-30) and reverse
(50-GCTCACGACTCCAATCTGAT-30) primer, 1ml (12.5ng) of b-
actin forward (50-GACATGGAGAAGATCTGGCA-30) and reverse
(50-ggtctttacggatgtcaacg-30) primer, and 0.5U of Red Hot DNA
polymerase (Advanced Biotechnologies, Epsom, UK). The PCR
program was as follows: 941C for 5min followed by 30 cycles of
941C for 30s, 561C for 30s and 721C for 90s with a final extension
of 721C for 10min. PCR products were analysed by agarose gel
analysis, purified using the Qiaex II gel extraction kit (Qiagen,
Clifton Hill, Australia) and sequenced using the Testisin reverse
primer and ABI PRISM BigDyet Terminator Cycle Sequencing
Reagent (Applied Biosystems, Foster City, CA, USA). PCR
amplification of Testisin mRNA (460bp product) was unaffected
by the amplification of b-actin mRNA (375bp product) in the
same reaction mixture (data not shown).
For quantitative real-time PCR, specific primers and fluores-
cent-labelled probes for Testisin (Hs 00199035_m1) and b-actin
(Hs 99999903_m1) were obtained from Assay-on-Demand Gene
Expression Products (Applied Biosystems). cDNA was synthesised
from RNA using the Taqman Reverse Transcription Reagents with
random primers (Applied Biosystems) according to ABI optimised
protocols (251C for 10min, 481C for 30min and 951C for 5min).
PCR was performed using the ABI PRISM 7900HT sequence
detector system. The thermal cycling conditions comprised an
initial denaturation step at 951C for 10min followed by 40 cycles at
951C for 15s, and then 601C for 1min. Expression levels of b-actin
were determined as an internal RNA control. Threshold cycle (CT)
was obtained from PCR reaction curves. Three replicates each
sample were analysed on two separate occasions to verify the
precision of the assay. The relative quantification of Testisin was
calculated using the comparative CT method as recommended by
Applied Biosystems with b-actin serving as the endogenous
reference: DCT (Testisin CT–b-actin CT); DDCT (DCT DCT of
untreated or control cell line), fold difference in target relative to
untreated (2
 (DDCT)).
Sodium-bisulphite genomic DNA modification and
sequence analysis
Genomic DNA from human tumour cell lines was extracted (Ciulla
et al, 1988) and bisulphite modified as previously described
(McDonald and Kay, 1997; Fitzpatrick et al, 1998). Genomic DNA
from primary tissue specimens was bisulphite modified utilising
low melting point agarose into which the DNA was embedded
(Olek et al, 1996). The desulphonated bisulphite modified genomic
DNA was amplified by two rounds of PCR using double nested
oligonucleotide primers in a 59–501C touchdown PCR protocol.
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CpG rich region ( 245 to þ115) overlapping the 50 end of the
Testisin CpG island (þ25 to þ873) (delineated using the Cpgplot
algorithm which utilises the standard criteria of Gardiner-Garden
and Frommer (Gardiner-Garden and Frommer, 1987)). The
amplified region spans the proximal promoter, the 50 untranslated
region, the transcription initiation site and exon I (Hooper et al,
1999, 2000). The primers for the first round of PCR were forward
50-TAGTTTGGGTAGAGATTTGGGGAGATTTTT-30 (224F), re-
verse 50-CTCCTACGACTCTACGAAAAACAAAAAATA-30 (T845).
The primers for the second round of PCR were forward 50-GAAG
GTTTTATGAAGGAGTAGTTATGTTTT-30 (293F), reverse 50-CTT
CCTAAATCCAAGCCGAACCAACAACAA-30 (733R). The
samples were sequenced using the 733R oligonucleotide primer
and ABI PRISM BigDyet Terminator Cycle Sequencing
Reagent (PE Applied Biosystems). All DNA samples were
bisulphite modified and sequenced in two to five indepen-
dent experiments.
A number of controls were included to monitor the efficiency of
sodium bisulphite modification and to ensure a lack of bias in the
PCR reactions. To verify that bisulphite treatment resulted in
complete conversion of unmethylated cytosines to uracil in each
genomic DNA sample, the complete conversion of every cytosine
not contained within a CpG site to uracil regardless of the
methylation status of the gene was monitored. Genomic DNA
isolated from HeLa and SW620 cells were included as unmethy-
lated and methylated controls respectively, as part of each
experiment to monitor PCR bias in the selective amplification of
unmethylated over methylated sequences or vice versa (Warnecke
et al, 1997). Bisulphite conversion was also conducted on mixtures
of methylated and unmethylated controls (i.e. 50% HeLa genomic
DNA/50% SW620 genomic DNA) to monitor bias in semimethy-
lated samples. These mixtures were sequenced to reproduce the
expected semimethylated signal on multiple occasions (data not
shown). The methylation status of the coding strand was
determined for all samples; verification of the methylation status
on the noncoding strand was performed for a subgroup of genomic
DNA samples and found to be consistent in all cases (data not
shown). The oligonucleotide primers used in the first round PCR
amplifying the noncoding DNA strand were forward 50-GCGA
TTTTGCGGGAGATAAGAAGTGATTTT-30 (TC535), reverse
(TC1160) 50-CAATAAAAACAACCTAAACAAAAACTTAAA-30.
The primers for the second round PCR were forward 50-TCGAG
TTTATTCGGTTTTTTGAGTTTAGTT-30 (TC628), reverse 50-AAA
ACTTAAAAAAATCCCCATTCTAAATAA-30 (TC1130).
In vitro demethylation and histone deacetylase inhibition
of human tumour cell lines
The human tumour cell lines Tera-2, SW620 and GCT27C-4 were
seeded at low density (2.5 10
5 cells), allowed to adhere overnight,
then treated with either 2–10mM 5-azacytidine (5-aza), 10–100nM
trichostatin A (TSA), 1–10mM 5-aza-20-deoxycytidine (5-aza-20)o r
combinations of these reagents for 3–4 days (2 days for TSA) with
the media changed every 24h. RT–PCR analysis as described
above using Testisin and b-actin oligonucleotide primers was
performed on cellular RNA.
Generation of stable transfectants
Full-length Testisin cDNA in pcDNA3 (Hooper et al, 1999) was
transfected into Tera-2 cells by electroporation (250mV, 960mF).
Clones resistant to G418 (0.1mgml
 1) (Invitrogen Australia, Pty
Ltd) were isolated and screened for Testisin mRNA expression by
RT–PCR as described above. Four independent clones expressing
Testisin mRNA (C1, C11, C29 and C33) and a cell line containing
the pcDNA3 vector alone (VOC2) were selected for subsequent
experiments.
In vivo orthotopic testicular tumour model
This model was performed essentially as we have published
previously (Douglas et al, 2001) using 7–8-week-old severe
combined immune deficient (SCID) mice (6–8 mice per group;
C.B.-17-SCID) (Australian Resource Centre, Perth, Western
Australia, Australia). Mice were housed in a temperature-
controlled, specific pathogen-free room (231C, 12h light–dark
regime) with free access to water and a standard diet (Norco,
Lismore, NSW, Australia). Tumour cells were implanted when the
mice were 8 weeks of age. The study was approved by the Group 5
Animal Experimental Ethics Committee of the University of
Queensland and performed according to NHMRC Guidelines
(AEEC Approval Number SURG/394/98, SURG/569/99; BCREC
Approval A9806-01-019M). Under general anaesthesia following
exteriorisation of the testes, Tera-2 clones isolated above were
injected into the left testis (1 10
6 cells in 25ml PBS). As an
internal control, the contralateral (right) testis was either injected
with an equal volume of PBS or not injected; no difference was
detected between the two methods. After 4 weeks, or when the
apparent tumour size approached 1cm
3, both testes were removed,
weighed and half was fixed in formalin for histological analyses
and the remaining half, frozen in liquid nitrogen for RT–PCR
analyses. The lungs were inflated with Bouin’s fixative and
removed for histological analyses. Testes weights were represented
as a percentage of total body weight in grams to correct for
differences in size between individual mice. Tumour burden was
calculated by dividing the value for the tumour-affected left testis
by that of the contralateral testis. These studies were performed
according to the Australian ‘Code of Practice for the Care and Use
of Animals for Scientific Purposes’. During the 4-week period of
tumour development, the mice exhibited no symptoms or signs of
clinical illness apart from a visible or palpable lump in the lower
abdomen or scrotum.
Immunohistochemistry
Paraffin sections (3–4mm) of mouse tissues were affixed to adhesive
slides and air-dried overnight at 371C. For immunohistochemistry,
sections were deparaffinised and immersed in methanol containing
0.3% H2O2 for 30min to exhaust endogenous peroxidase activity. After
thorough washing, the sections were preincubated with 10% horse
serum, followed by anti-Testisin monoclonal antibody (DD-P104 C37;
diaDexus, Inc., South San Francisco) at 8mgml
 1 for 1h at room
temperature. After washing in PBS, biotinylated anti-mouse IgG was
applied for 30min at room temperature. The sections were washed
thoroughly in PBS before incubating in Vectastain ABC reagent for
30min at room temperature. Sections were developed by incubation in
0.05% 3,30-diaminobenzidine (DAB) in Tris-HCl, pH 7.4 buffer with
H2O2 as substrate. After washing in water, the sections were lightly
counterstained with Mayer’s haematoxylin. Negative controls were
stained as above but with PBS substituted for the primary antibody.
Histology sections were stained with Mayer’s haematoxylin and eosin.
In vitro cell proliferation assay
Tera-2 cells were seeded in 96-well tissue culture plates (Costar) in
triplicate at low (1000 cells), medium (5000 cells) and high (10000
cells) density and allowed to grow for 2, 3 or 4 days under normal
culture conditions. Cell proliferation was assayed by 5-bromo-20-
deoxyuridine (BrdU) (colorimetric) ELISA (Roche) as per the
manufacturer’s instructions. The assay was replicated on four
separate occasions.
In vitro colony forming assays
For monolayer assays, cells were plated in six-well plates (100 cells
per well) in triplicate and cultured for 14 days with the media
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violet and colonies of greater than 50 cells were counted. For assay
of colony formation in soft agarose, cells were embedded in 0.33%
agarose, which was sandwiched between a 0.6% agarose base and a
0.33% top layer with media, in triplicate in six-well plates. Plates
were incubated for 4 weeks under normal culture conditions. The
number and approximate colony sizes were recorded.
Statistical analyses
The nonparametric Mann–Whitney test was used to determine
differences between two groups, and the nonparametric Kruskal–
Wallis test was used for the analysis of differences among more
than two groups. Po0.05 was considered statistically significant.
RESULTS
Testisin gene silencing correlates with DNA
hypermethylation in human tumour cell lines
As reported previously (Hooper et al, 1999), the Testisin gene
contains a 50 CpG island and an overlapping CpG rich region
spanning nucleotides  245 to þ873 which encompasses the
Testisin proximal promoter, the 50-untranslated region and the
beginning of exon I (Figure 1, top). To investigate whether Testisin
expression may be associated with the methylation status of the 21
CpG dinucleotides in the 385bp 50 CpG island, sodium bisulphite
sequence analysis was utilised. This technique enables the
methylation status of individual CpG sites in a region to be
determined by selective conversion of unmethylated cytosines, but
not methylated cytosines, to uracil, following treatment of the DNA
with sodium bisulphite. Analysis of genomic DNAs isolated from
Testisin-expressing (HeLa, SiHa and PEO4) and non-Testisin
expressing (GCT27C-4, Tera-2, SW620 and U937) tumour cell lines
showed that Testisin expressing cell lines contained very few
methylated CpG sites (o20%) within this region, whereas the non-
Testisin expressing cell lines showed a high percentage (490%) of
fully methylated CpG sites (Figure 1). These data show that
Testisin gene expression correlates with hypermethylation of the
CpG sites within this 385bp region and point to a role for CpG
methylation in the regulation of Testisin gene expression.
The Testisin gene is hypermethylated in primary TGCT
We have demonstrated previously that while Testisin is present in
testicular spermatocytes, TGCTs lack Testisin expression (Hooper
et al, 1999). Detection of Testisin mRNA by RT–PCR amplification
of RNA isolated from seven sets of primary tissue specimens
(consisting of tumour and adjacent normal tissues from the same
patient) confirmed the absence of Testisin mRNA in the testicular
tumour tissues (Figure 2A). To determine whether the silencing of
Testisin gene expression in the testicular tumours was associated
with methylation of the 385bp 50 CpG region, sodium bisulphite
sequencing analysis was performed on genomic DNA isolated from
these tissue specimens. The majority of the CpG sites within the
Testisin 50 CpG island in the normal, unaffected testis tissues were
unmethylated (an average of 18.6% methylated CpG sites)
(Figure 2B). The 50 untranslated region and exon I contained
predominantly unmethylated CpG sites, with only three specimens
showing evidence of partial methylation. The proximal promoter
region was largely unmethylated but similarly contained some
methylated CpG sites. Unusually, genomic DNA from one patient
(#795) showed methylation of all six CpG sites within this region,
despite evidence of Testisin mRNA expression by RT–PCR. In the
testicular tumour tissues, the majority of the CpG sites were
methylated (an average of 86.4% of methylated CpG sites)
(Figure 2C). There appeared to be an increased number of
semimethylated CpG sites in the 50 untranslated region of the
Testisin gene in the tumour specimens compared with the large
number of methylated sites in the proximal promoter and exon I.
Thus, the Testisin gene methylation patterns and silencing
observed in testicular tumour cell lines reflects aberrations present
in primary testicular tissues. Taken together, these data demon-
strated a clear inverse correlation between the methylation status
Source of DNA (N = 2)
Testisin 
expression
Promoter region
−272 21 26 39 44 50 53 55 74
GCT27C-4 − testicular tumour cell line −
Tera-2 − testicular tumour cell line −
SW620 − colon carcinoma cell line −
U937 − monocytic cell line −
HeLa − cervical carcinoma cell line +
SiHa − cervical carcinoma cell line +
PEO4 − ovarian carcinoma cell line +
3′ 5′
−272     −187
−187
−166
−166
−122 
−122 
−85
−85
−60 
−60 
  +21   +74 +114
50 bp
tis
5´UTR
5´UTR
Exon 1
Exon 1
5′ promoter
Pgk2 AP1 Sp1/H1t SRY Sp1/Sp1
CpG site
82 84 103 105 107 109 114 methylated
97.6%
100.0%
92.8%
91.6%
0.0%
19.0%
4.8%
Figure 1 Testisin expression correlates with DNA hypermethylation in human tumour cell lines. The upper diagram shows a schematic illustration of the
Testisin 50 CpG island analysed by bisulphite sequencing. Thin vertical bars map the location of 21 CpG sites analysed within this region. The transcription
initiation site (tis) is indicated by the right-angled arrow. Sites that conform to the consensus binding elements for Sp1, AP1 and SRY, and the regulatory
elements associated with transcription of testis-specific proteins H1t and Pgk2 are indicated by bold black boxes. The table shows the results of sequence
analysis within the Testisin 50 CpG island of bisulphite treated genomic DNA isolated from non-Testisin expressing tumour lines (GCT27C-4, Tera-2,
SW620 and U937) and Testisin expressing tumour lines (HeLa, SiHa and PEO4). Expression of Testisin mRNA (indicated by þ) was determined by RT–
PCR (data not shown). The percentage of CpG sites methylated per cell line was calculated by adding the score of each CpG site and dividing by (the total
number of sites analysed multiplied by 2), giving a maximum total of 42. The scoring and representative symbols are as follows: fully methylated CpG site
(black shaded square; score¼2); fully unmethylated CpG site (unshaded square; score¼0); a semimethylated CpG site where the methylated signal is
stronger than the unmethylated signal (hashed triangle; score¼1.5); a semimethylated CpG site where the unmethylated signal is stronger than the
methylated signal (unhashed triangle; score¼0.5). The data represents a 3–5 independent bisulphite sequencing experiments.
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both tumour cell lines and primary testicular tumours. These
results suggest that hypermethylation of the Testisin gene is
involved in silencing of the Testisin gene in TGCT.
Reactivation of Testisin mRNA expression by
demethylation and histone deacetylase inhibition
Methylated promoter DNA may interfere with binding of
transcription factors or other CpG binding proteins to silence
gene transcription, and histone deacetylases may act synergisti-
cally in conjunction with DNA methylation to co-repress gene
expression (Cameron et al, 1999). It has been found that
expression of genes silenced by promoter methylation may be
restored by treatment of cells with the demethylating agents 5-aza
or 5-aza-20-deoxycytidine (5-aza-20), and combined treatment with
a histone deacetylase inhibitor can further stimulate re-expression
(Esteller, 2002). To investigate whether the Testisin gene may be
reactivated following demethylation of CpG sites and/or histone
deacetylase inhibition, Testisin-nonexpressing tumour cell lines
were treated with the demethylating agents, 5-azacytidine, 5-aza-
20-deoxycytidine, and/or the histone deacetylase inhibitor TSA.
Testisin mRNA expression was followed by RT–PCR analysis and
co-amplification of b-actin mRNA confirmed the quality of the
total RNA used in each reaction. The upregulation of Testisin
mRNA expression following treatment was quantitated by real-
time RT–PCR. Testisin mRNA was induced in SW620 cells after
treatment with 10mM 5-azacytidine (Figure 3A), and was induced
in Tera-2 cells following treatment with as low as 2mM 5-
azacytidine (Figure 3B). The demethylating agent, 5-aza-20-
deoxycytidine, also induced Testisin mRNA expression in both
SW620 (Figure 3A) and Tera-2 cells (Figure 3B) at 10mM. TSA
induced very low to negligible levels of Testisin mRNA expression
in SW620 cells, which increased when TSA was used in
combination with 5-azacytidine (Figure 3A). TSA alone did not
induce Testisin mRNA in Tera-2 cells, but was more effective in
combination with 5-azacytidine (Figure 3B). GCT27C-4 cells were
sensitive to TSA treatment, with Testisin mRNA expression
observed after treatment with 10 and 100nM TSA (Figure 3C).
Interestingly, 5-azacytidine appeared to have a negative effect on
the upregulation of Testisin mRNA induced by TSA in these
cells. The presence of doublet Testisin bands in Tera-2 and
GCT27C-4 cells is due to a splice variant of the Testisin tran-
script, resulting in the deletion of 40bp of exon 5 (data not shown).
This Testisin isoform has been reported previously (Inoue
et al, 1999), although its significance is not known. In all cases,
Testisin mRNA re-expression was accompanied by partial
demethylation of the Testisin 50 CpG region as determined by
bisulphite sequencing (data not shown). These data further
confirm that Testisin is silenced in testicular tumour cells by
hypermethylation.
Expression of Testisin mRNA reduced the tumorigenicity
of Tera-2 cells in an orthotopic xenograft model of
testicular tumorigenesis
Our findings show that Testisin mRNA expression is silenced in
testicular tumour cells through a mechanism involving DNA
hypermethylation of the Testisin gene. To investigate whether
inactivation of the Testisin gene may confer a selective advantage
to testicular tumorigenicity, the effect of expression of the Testisin
gene in Tera-2 cells, which lack Testisin gene expression and form
tumours when implanted in an orthotopic model of testicular
tumorigenesis (Douglas et al, 2001), was investigated.
An expression plasmid containing Testisin cDNA or the control
vector alone were transfected into Tera-2 cells and stable cell lines
isolated on the basis of G418 resistance. Four independent clones,
C1, C11, C29 and C33, expressing Testisin mRNA (Figure 4A) and
Source of DNA (N = 2) 
Source of DNA (N = 2) 
Age Testisin Promoter region
Promoter region
 5′ UTR
 5′ UTR
expression
Testisin
expression
−272 −187 −166 −122 −85 −60 21 26 39
−272 −187 −166 −122 −85 −60 21 26 39
44 50 53 55 74
# 798 − matched normal  testis  27 +
# 438 − matched normal  testis  44 +
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Figure 2 Silencing of the Testisin gene in testicular germ cell tumours is associated with DNA hypermethylation. (A) Testisin mRNA expression in
representative primary human tissue specimens. RNA isolated from testicular tumour (T) and unaffected adjacent normal tissues (N) from individual patients
was evaluated by RT–PCR for Testisin mRNA expression. b-Actin mRNA was monitored as a measure of mRNA concentration and integrity. The tables
show the results of sequence analysis of the Testisin 50 CpG island of bisulphite treated genomic DNA isolated from matched primary tissues from individual
patients: unaffected ‘normal’ testicular tissue adjacent to tumour (B) and testicular tumour tissues (C). The symbols and the percentage methylated CpG
sites were calculated as described in the legend to Figure 1. The data are representative of a minimum of two independent bisulphite sequencing
experiments.
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sa vector alone control (VOC2) were selected and used for
tumorigenicity studies. Clones expressing Testisin mRNA sup-
pressed the tumorigenicity compared with the Tera-2 parent line
and the vector alone control Tera-2 cells (Figure 4B). The observed
growth suppression appeared to correlate with Testisin mRNA
expression level; clones C1 and C11 showed the highest Testisin
mRNA expression and the least tumour burden. Growth suppres-
sion was replicated in three independent experiments. After the
4-week period of in vivo tumour growth, all tumours were removed
and Testisin expressing clones shown to have maintained human
Testisin mRNA expression by RT–PCR (data not shown).
Morphological analysis of tissue specimens showed that growth
of the parental Tera-2 cells or the control (vector alone) tumour
cells resulted in virtual replacement of the affected testis with the
growing mass of tumour cells. Tumour growth blocked the blood
supply to the seminiferous tubules causing widespread severe
atrophic changes in residual seminiferous tubules (Figures 5A
and B). Each of the Testisin mRNA expressing Tera-2 clones
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Figure 3 Reactivation of the Testisin gene following demethylation and histone deacetylase inhibition. Reactivation of Testisin in SW620 cells (A), Tera-2
cells (B), and GCT27C-4 cells (C) after treatment with 2–10mM 5-azacytidine (5-aza), 1–10mM 5-aza-20-deoxycytidine (5-aza-20) and/or 10–100nM
Trichostatin A (TSA) alone or in combination. RT–PCR was performed using 3ml of cDNA in the presence of Testisin and b-actin oligonucleotide primers
for 40 cycles at 561C annealing temperature. Two PCR products encoding Testisin are detected in Tera-2 and GCT27C-4 cells due to the expression of an
alternate splice variant, which is missing the terminal 40bp of exon 5 (determined by DNA sequence analysis, data not shown). Representative results from
2–4 independent experiments are shown. To the right of the DNA gels are shown the results of quantitative analysis of Testisin mRNA transcripts under
each given condition as determined by real-time quantitative PCR. A value of 1 is arbitrarily set for the untreated control cell line. The data is representative
of two independent experiments performed in triplicate.
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s(C1, C11, C29 and C33) demonstrated reduced tumour burden
relative to the parental and vector only lines, and visibly displaced
less of the testis causing fewer disruptions to the blood supply.
Moderate atrophy was seen in the seminiferous tubules surrounding
several clones (for example, Figure 5C). Only mild atrophy was
seen in the seminiferous tubules for C11 (Figures 5D and E).
Stained sections of contralateral (right) testes showed normal
morphology independent of tumour growth in the left testis (inset
Figure 5). Testisin staining of tumour sections using an anti-
Testisin monoclonal antibody showed light, patchy staining of
tumour tissue relative to Testisin staining of germ cells (Figure 5F).
No lung metastases were detected in any of the experimental
animals, independent of Testisin expression in the testicular
tumours (data not shown).
Re-expression of Testisin mRNA inhibited in vitro colony
formation
The suppression of Tera-2 tumour growth in vivo suggests that the
Testisin gene may function as a tumour suppressor. Expression of
Testisin mRNA did not affect Tera-2 in vitro cell proliferation as
assessed by BrdU incorporation (data not shown). In addition, no
alterations in cell viability or cell morphology under normal
culture conditions in vitro were observed (data not shown). As in
vitro growth of Tera-2 cells is anchorage-dependent, the effect of
Testisin mRNA expression on Tera-2 malignant potential in vitro
was examined by colony forming assay in monolayer. Tera-2
clones expressing Testisin mRNA formed fewer colonies than the
parent line or pcDNA3 vector only clones (Po0.005) (Figure 4C),
consistent with the suppressed tumorigenicity observed in vivo.
Testisin mRNA expression in Tera-2 cells did not confer
anchorage-independent growth as measured by colony formation
in agarose (data not shown).
DISCUSSION
The Testisin gene is specifically expressed by meiotic germ cells in
human testis (Hooper et al, 1999), and is absent in TGCT (Hooper
et al, 1999), suggesting it is a candidate tumour suppressor gene
for testicular tumours. Here we demonstrate that the Testisin gene
is regulated by DNA methylation and that hypermethylation of the
Testisin 50 CpG island represents a principal mechanism for
inactivating this gene in testicular cancers (Figures 1 and 2).
Further we provide the first functional evidence that re-activation
of Testisin gene expression, through exogenous expression of
Testisin cDNA, suppresses in vivo testicular tumour growth and
colony forming ability in vitro, supporting the hypothesis
that Testisin inactivation confers a selectable advantage for
testicular tumours.
That the Testisin gene is silenced by DNA hypermethylation was
demonstrated by (i) the correlation of CpG island methylation
status with gene expression in tumour cell lines and in primary
testicular tumour tissues (Figures 1 and 2) and (ii) re-expression of
Testisin mRNA following demethylation and histone deacetylase
inhibition (Figure 3). Thus, Testisin may be added to an emerging
list of tumour suppressor genes that are silenced by DNA
hypermethylation, including prostasin (Chen and Chai, 2002),
E-cadherin (Melki et al, 2000; Nakayama et al, 2001), normal
epithelial cell-specific 1 (NES1) (Li et al, 2001) and COX-2
(Kikuchi et al, 2002).
Mechanisms of silencing of gene transcription by DNA
methylation occur either through methylation of specific CpG
dinucleotides contained within the binding sites for transcription
factors (Tate and Bird, 1993) or through methylation of a region of
CpG dinucleotides resulting in binding of methyl CpG proteins to
the DNA that in turn inhibit access of regulatory elements to the
DNA and inhibit transcription (Boyes and Bird, 1992). The Testisin
50 CpG island contains four CpG dinucleotides located wholly or
partially within the binding sites for transcription factors Sp1
[(þ20 to þ26); (þ26 to þ31); ( 86 to  81)] and AP1 ( 184 to
 190) and the testis-specific regulatory element, CCCCACCC
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Figure 4 Expression of the Testisin gene suppresses tumorigenicity of
Tera-2 cells in vivo and inhibits anchorage-dependent colony formation in
vitro.( A) Testisin mRNA expression in transfected Tera-2 cell lines. Graph
showing fold difference in Testisin mRNA expression levels relative to b-
actin determined by quantitative real-time PCR: mRNA isolated from
parental Tera-2 cells [T2], Tera-2 clones transfected with Testisin cDNA
[C1, C11, C29, C33] or the control Tera-2 clone transfected with vector
alone [VOC2]. (B) Testisin gene expression suppresses Tera-2 tumour
growth in a murine in vivo orthotopic xenograft model of testicular
tumorigenesis. Tumour burden (testis tumour weight as a percentage of
the total mouse body weight) was calculated as described in the Materials
and Methods and is displayed as a scattergram with the line centered on
the mean of the values. C1, C11, C29, C33 vs VOC2, P¼0.0022; Kruskal–
Wallis nonparametric test. There was no significant difference between
parental Tera-2 cells and the vector alone control, T2 vs VOC2, P¼0.0877.
(C) Testisin gene expression inhibits anchorage-dependent colony forming
ability of Tera-2 cells in-vitro. Cells were plated at low density and colony
formation monitored over 14 days with media changed every 4 days. C1,
C11, C29, C33 vs VOC2, P¼0.0022; Kruskal–Wallis nonparametric test.
There was no significant difference between parental Tera-2 cells and the
vector alone control, T2 vs VOC2, P¼0.1320.
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s( 279 to  272) that is homologous to that found in the Pgk2 gene
(Hooper et al, 2000). Furthermore, the Sp1 site at ( 81 to  86) is
required for minimal Testisin promoter activity in HeLa cells as
demonstrated by reporter gene assay (Inoue et al, 1999). This may
indicate that the methylation status of these four CpG dinucleo-
tides plays a primary role in Testisin gene regulation. However, the
present studies suggest that while partial demethylation was
detected in the proximal promoter region of the Testisin gene,
there was consistently more demethylation of CpG dinucleotides
within the 50 untranslated region (Figures 1 and 2B). It has been
proposed that methylation of CpG dinucleotides near transcription
initiation sites may strongly inhibit gene transcription by
inhibiting the setting of the basal transcription machinery (De
Smet et al, 1999). This mechanism of gene suppression has been
suggested for other genes, for example, HPRT, PGK1, which, like
PRSS21, contain CpG-rich TATA-less promoters (De Smet et al,
1999). Thus, the Testisin 50 untranslated region may play a primary
role in silencing of gene transcription, possibly via binding of
methyl CpG proteins to CpG dinucleotides in the vicinity of the
transcription initiation site. The synergy between the demethylat-
ing agents and histone deactylase inhibitors to reactivate Testisin
gene expression indicates that in addition to DNA methylation and
the methyl CpG proteins, other indirect epigenetic mechanisms,
such as histone modifying enzymes and chromatin, are working
together to silence Testisin gene expression.
The semimethylated CpG sites observed in the 50 untranslated
region of testicular tumour tissues may reflect some heterogeneity
in these tissues. It is likely the tissues are comprised of mixed
tumour cell types and also infiltrating cells, such as inflammatory
cells and lymphocytes that may contribute to the heterogeneity
(Heidenreich et al, 1998). Alternatively, the semimethylated CpG
sites may indicate that not all CpG sites within the Testisin 50
untranslated region need to be fully methylated for the Testisin
gene to be silenced. It was surprising that the Testisin 50 CpG
island was essentially unmethylated in normal testis, given that the
Testisin gene is only expressed by a small population of cells, the
meiotic spermatocytes among the germ cells at various stages of
maturation (Hooper et al, 1999), and not by other somatic cells
present in the testis (Sertoli and Leydig cells). It is probable that
mechanisms other than DNA methylation are responsible for the
cell- and maturation-specific regulation of the Testisin gene. Thus,
epigenetic gene silencing, reflected by the observed hypermethyla-
tion of the Testisin 50 CpG island, represents a mechanism that
appears to be tumour-specific.
While hypermethylation of the Testisin 50 CpG island is most
likely responsible for the silencing of Testisin in testicular
tumours, it is unclear whether this represents a cause or
consequence of testicular tumorigenesis (Herman, 1999). Knud-
son’s two hit theory of tumour-suppressor gene inactivation
proposes inactivation of one allele by a mutation or epigenetic
event followed by inactivation of the second allele by a large
chromosome deletion or other event during tumour growth
(Knudson Jr, 1986). Hypermethylation of tumour DNA has been
shown to occur in chromosomal regions that undergo LOH,
suggesting a causative link between the two phenomena (Baylin
et al, 1991). Hypermethylation of the Testisin 50 CpG island and
the loss of Testisin expression in TGCT suggest that hypermethy-
lation of the Testisin gene could be functionally relevant for
testicular tumorigenesis.
The finding of gene silencing associated with hypermethylation
has precedents with two other protease genes. The NES1 serine
protease gene is downregulated in breast and prostate cancers, and
its expression is associated with a tumour suppressor function
(Goyal et al, 1998; Luo et al, 2001). The prostasin gene is
downregulated in prostate cancers and its expression functionally
inhibits both prostate (Chen et al, 2001, 2004) and breast cancer
invasiveness (Chen and Chai, 2002). Similar to our observations on
the Testisin gene, hypermethylation of both prostasin and NES1
genes has been reported as the basis for loss of expression of these
genes in tumours (Li et al, 2001; Chen and Chai, 2002), and their
effects on cells are not associated with reduced proliferation (Goyal
et al, 1998; Chen et al, 2001). Taken together, these findings
support an emerging new paradigm for serine protease genes
wherein they may be silenced by epigenetic mechanisms leading to
enhanced tumorigenesis. In contrast to the inhibitory effect of
Testisin expression on testicular tumorigenesis, Testisin over-
expression has been associated with advanced stage disease in
ovarian carcinomas (Shigemasa et al, 2000). These data indicate
Figure 5 Photomicrographs of histological analyses of murine orthotopic testicular tumours. Tissue sections were stained with Mayers’ haematoxylin and
eosin. (A, B) Examples of severely atrophied residual seminiferous tubules (s) present in testes containing testicular tumours (t) formed after 4 weeks
following injection of the vector alone cell line control. (A) and (B) are  100 and  400 magnification respectively. (C) Representative residual
seminiferous tubule with moderate atrophic changes present in testes 4 weeks following injection of C33 ( 100 magnification). (D, E) Examples of residual
seminiferous tubules with mild atrophic changes after 4 weeks following injection of C11, at magnifications of  100 and  400, respectively. (F)
Immunohistochemical staining for Testisin in a section containing C11 tumour at  400 magnification. The monoclonal antibody (DD-P104 C37) reacts with
human Testisin present in the tumour (t) as well as murine Testisin present in the round (r) and elongating spermatids (es) of the murine seminiferous
tubules. The inset ( 100 original magnification) shows a contralateral testis with normal morphology.
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sthat the effect of Testisin on tumour growth and survival are
further dependent on the cellular context and tumour
microenvironment. Cell surface expression of a protease by a
tumour cell will lead to activities dependent on available
proteolytic targets, and these may be quite different in different
tissue environments, particularly if the protease is not normally
expressed in that tissue.
The data presented here demonstrate that Testisin gene
silencing is associated with hypermethylation of the Testisin CpG
island in primary testicular cancers and support a role for Testisin
as a tumour suppressor in testicular cancers. The inactivation of a
tumour suppressor gene through epigenetic mechanisms leaves the
gene structure intact and provides for the therapeutic possibility
that the gene can be re-activated in vivo allowing for the ‘tumour
suppressor’ function of the gene to be restored (reviewed in
Esteller, 2002). This in vivo re-activation is currently being used
in the clinical setting to re-express foetal haemoglobin to treat
sickle cell anaemia (Koshy et al, 2000). The re-expression of Testisin
and other tumour suppressor genes could be initiated by a
similar treatment if issues relating to toxicity could be resolved
(Christman, 2002).
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